PAT margin for Q1 FY24 is 15.4 per cent
Dr Lal PathLabs announces their financial results for the quarter ended June 30, 2023.
Consolidated performance highlights: Q1 FY 2023-24 vs Q1 FY 2022-23
- Non-COVID revenue increased by 9.7 per cent in Q1 FY24
- Normalised EBITDA margin (after adjustment for stock based compensation & CSR) for Q1 FY24 is 28.4 per cent
- PAT margin for Q1 FY24 is 15.4 per cent
Financial overview (Consolidated) in Rs Cr
- Advertisement -